Palatin Technologies (PTN) Change in Receivables (2010 - 2025)
Palatin Technologies' (PTN) quarterly Change in Receivables came in at -$5.3 million in Q4 2025, down 176.24% on a QoQ basis from $6.9 million in Q3 2025.
Palatin Technologies (PTN) Change in Receivables (2010 - 2025) Analysis & Trends
Palatin Technologies (PTN) has 13 years of Change in Receivables data on file, last reported at -$5.3 million in Q4 2025.
- Quarterly Change in Receivables changed N/A year-over-year to -$5.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.6 million (up 169.74% YoY) and the FY2024 annual result came in at -$2.9 million, down 156.73% from the prior year.
- Change in Receivables fell to -$5.3 million in Q4 2025, from $6.9 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $6.9 million in Q3 2025 to a low of -$5.3 million in Q4 2025.
- A 5-year average of -$98728.8 and a median of $107880.0 in 2023 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2023 — Change in Receivables surged 745.68% — and 2024, when it plunged 2274.79%.
- Tracing PTN's Change in Receivables over 5 years: stood at -$1.7 million in 2021, then soared by 112.98% to $215760.0 in 2022, then sank by 1090.39% to -$2.1 million in 2023, then retreated by 9.8% to -$2.3 million in 2024, then tumbled by 123.77% to -$5.3 million in 2025.
- The last three Change in Receivables figures came in at -$5.3 million (Q4 2025), $6.9 million (Q3 2025), and -$2.3 million (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.25 Mn |
| Dec 31, 2025 | -5.25 Mn |
| Sep 30, 2025 | 6.89 Mn |
| Sep 30, 2025 | 6.89 Mn |
| Mar 31, 2024 | -2.35 Mn |
| Mar 31, 2024 | -2.35 Mn |
| Dec 31, 2023 | -2.14 Mn |
| Dec 31, 2023 | -2.14 Mn |
| Sep 30, 2023 | 1.57 Mn |
| Sep 30, 2023 | 1.57 Mn |
| Jun 30, 2023 | -1.22 Mn |
| Jun 30, 2023 | -1.22 Mn |
| Mar 31, 2023 | 107,880.00 |
| Mar 31, 2023 | 107,880.00 |
| Dec 31, 2022 | 215,760.00 |
| Dec 31, 2022 | 215,760.00 |
| Sep 30, 2022 | -242,730.00 |
| Sep 30, 2022 | -242,730.00 |
| Jun 30, 2022 | 590,861.00 |
| Jun 30, 2022 | 590,861.00 |